Cartesian Therapeutics Depreciation & Amortization Growth & History (RNAC)
Cartesian Therapeutics's depreciation and amortization was $3.2M for fiscal 2025.
View full Cartesian Therapeutics company overviewCartesian Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.2M | −$459,000 | −12.62% |
| 2024 | 2024-12-31 | $3.6M | $1.2M | +48.21% |
| 2023 | 2023-12-31 | $2.5M | $417,000 | +20.47% |
| 2022 | 2022-12-31 | $2.0M | $318,000 | +18.50% |
| 2021 | 2021-12-31 | $1.7M | −$8,000 | −0.46% |
| 2020 | 2020-12-31 | $1.7M | −$274,000 | −13.69% |
| 2019 | 2019-12-31 | $2.0M | $1.0M | +100.10% |
| 2018 | 2018-12-31 | $1.0M | $250,000 | +33.33% |
| 2017 | 2017-12-31 | $750,000 | −$52,000 | −6.48% |
| 2016 | 2016-12-31 | $802,000 | −$242,000 | −23.18% |
| 2015 | 2015-12-31 | $1.0M | $180,000 | +20.83% |
| 2014 | 2014-12-31 | $864,000 | — | — |
Cartesian Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.0M | $255,000 | +32.40% |
| Q1 2026 | 2026-03-31 | $835,000 | $51,000 | +6.51% |
| Q4 2025 | 2025-12-31 | $608,000 | — | — |
| Q3 2025 | 2025-09-30 | $792,000 | −$161,000 | −16.89% |
| Q2 2025 | 2025-06-30 | $787,000 | −$14,000 | −1.75% |
| Q1 2025 | 2025-03-31 | $784,000 | $72,000 | +10.11% |
| Q3 2024 | 2024-09-30 | $953,000 | $417,000 | +77.80% |
| Q2 2024 | 2024-06-30 | $801,000 | $175,000 | +27.96% |
| Q1 2024 | 2024-03-31 | $712,000 | $96,000 | +15.58% |
| Q3 2023 | 2023-09-30 | $536,000 | −$3,000 | −0.56% |
| Q2 2023 | 2023-06-30 | $626,000 | $128,000 | +25.70% |
| Q1 2023 | 2023-03-31 | $616,000 | $223,000 | +56.74% |
| Q3 2022 | 2022-09-30 | $539,000 | $156,000 | +40.73% |
| Q2 2022 | 2022-06-30 | $498,000 | $21,000 | +4.40% |
| Q1 2022 | 2022-03-31 | $393,000 | $21,000 | +5.65% |
| Q3 2021 | 2021-09-30 | $383,000 | $24,000 | +6.69% |
| Q2 2021 | 2021-06-30 | $477,000 | $41,000 | +9.40% |
| Q1 2021 | 2021-03-31 | $372,000 | −$194,000 | −34.28% |
| Q3 2020 | 2020-09-30 | $359,000 | −$126,000 | −25.98% |
| Q2 2020 | 2020-06-30 | $436,000 | −$41,000 | −8.60% |
| Q1 2020 | 2020-03-31 | $566,000 | −$61,000 | −9.73% |
| Q3 2019 | 2019-09-30 | $485,000 | $285,000 | +142.50% |
| Q2 2019 | 2019-06-30 | $477,000 | $77,000 | +19.25% |
| Q1 2019 | 2019-03-31 | $627,000 | $458,000 | +271.01% |
| Q3 2018 | 2018-09-30 | $200,000 | $0 | 0.00% |
| Q2 2018 | 2018-06-30 | $400,000 | $200,000 | +100.00% |
| Q1 2018 | 2018-03-31 | $169,000 | −$31,000 | −15.50% |
| Q3 2017 | 2017-09-30 | $200,000 | $100,000 | +100.00% |
| Q2 2017 | 2017-06-30 | $200,000 | $0 | 0.00% |
| Q1 2017 | 2017-03-31 | $200,000 | $22,000 | +12.36% |
| Q3 2016 | 2016-09-30 | $100,000 | −$100,000 | −50.00% |
| Q2 2016 | 2016-06-30 | $200,000 | −$300,000 | −60.00% |
| Q1 2016 | 2016-03-31 | $178,000 | — | — |
| Q3 2015 | 2015-09-30 | $200,000 | — | — |
| Q2 2015 | 2015-06-30 | $500,000 | — | — |
Cartesian Therapeutics depreciation and amortization trends
Over the last five fiscal years, Cartesian Therapeutics's depreciation and amortization increased from $1.7M to $3.2M, a change of $1.5M. The latest reported quarter, Q2 2026, shows $1.0M.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cartesian Therapeutics source filings ↗